Diploma (LON:DPLM) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Diploma (LON:DPLM) to an outperform rating in a report issued on Friday morning, Marketbeat.com reports. Royal Bank Of Canada currently has GBX 6,000 target price on the stock, up from their prior target price of GBX 4,500.

A number of other equities analysts also recently issued reports on DPLM. Berenberg Bank raised their price target on Diploma from GBX 5,750 to GBX 6,350 and gave the stock a “buy” rating in a research note on Wednesday, September 10th. Jefferies Financial Group raised their price target on Diploma from GBX 4,500 to GBX 5,200 and gave the stock a “hold” rating in a research note on Thursday, September 11th. Shore Capital restated a “hold” rating and issued a GBX 5,100 price target on shares of Diploma in a research note on Thursday, July 17th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 4,440 target price on shares of Diploma in a report on Wednesday, August 6th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 5,365.

Diploma Stock Performance

DPLM stock opened at GBX 5,362.50 on Friday. The company has a market cap of £7.19 billion, a P/E ratio of 4,314.16, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. Diploma has a 1 year low of GBX 3,532 and a 1 year high of GBX 5,625. The company has a debt-to-equity ratio of 62.17, a current ratio of 2.17 and a quick ratio of 0.80. The stock’s fifty day moving average price is GBX 5,387.22 and its 200-day moving average price is GBX 4,750.90.

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.